Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Business Update | Thu 11, 2021
BottNeuro advancing personalized alzheimer’s therapy
Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient’s brain are stimula
Business Update | Thu 07, 2021
Bottneuro passes 2nd stage of Venture Kick: CHF 40'000.-
Bottneuro was selected by the Venture Kick's jury of experts as one of the winners of the second stage of financial and entrepreneurial support.
Business Update | Tue 03, 2021
BottNeuro passes 1st stage of Venture Kick: CHF 10'000.-
Bottneuro, together with Aegis Rider, Arkaïya, Celerato, and voltWALL win Venture Kick's first stage of financial and entrepreneurial support. Their p
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
